# C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection

> **NCT02936479** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 1 (actual)

## Conditions studied

- Antibody Mediated Rejection of Kidney Transplant

## Interventions

- **DRUG:** C1-INH (Berinert)

## Key facts

- **NCT ID:** NCT02936479
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-10-30
- **Final completion:** 2018-10-30
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936479, "C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02936479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*